Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Article in Press
Brief Report
Case Report
Case Report and Review
Case Reports
Case Series
Commentary
Editorial
Erratum
How do I do it
How I do it?
Invited Editorial
Letter to Editor
Letter to Editor/Case Reports/Images
Letter to the Editor
Letters to Editor
Letters to the Editor
Mini Review
Original Article
Original Articles
Original Research
Other Type
Others
Review Article
Short Paper
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Article in Press
Brief Report
Case Report
Case Report and Review
Case Reports
Case Series
Commentary
Editorial
Erratum
How do I do it
How I do it?
Invited Editorial
Letter to Editor
Letter to Editor/Case Reports/Images
Letter to the Editor
Letters to Editor
Letters to the Editor
Mini Review
Original Article
Original Articles
Original Research
Other Type
Others
Review Article
Short Paper
View/Download PDF

Translate this page into:

Original Article
1 (
2
); 53-55
doi:
10.4103/0974-2727.59699

Emergence of Nonalbicans Candida in Neonatal Septicemia and Antifungal Susceptibility: Experience from a Tertiary Care Center

Department of Microbiology, Pt. B.D.S. PGIMS, Rohtak, India
Department of Pediatrics, Pt. B.D.S. PGIMS, Rohtak, India
Address for correspondence: Dr. Nidhi Goel, E-mail: ngoel_2003@yahoo.com
Licence
This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0
Disclaimer:
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Aims:

To know the distribution and antifungal susceptibility pattern of Candida species in neonatal septicemia cases.

Materials and Methods:

In a prospective analysis blood samples from 825 clinically suspected cases of neonatal septicemia, collected aseptically, were cultured to look for the role of Candida spp. in septicemia. Candida isolates were speciated by germ tube test, Hi-CHROME agar, sugar fermentation, and sugar assimilation tests using standard protocol. All the Candida isolates were tested for antifungal susceptibility to fluconazole by the Disk Diffusion (DD) method and broth micro dilution-minimum inhibitory concentration (BMD-MIC) method using NCCLS guidelines.

Results:

Isolation rate of Candida from neonatal septicemia cases was 8.1%. Most common isolate was C. tropicalis (61.19%), followed by C. albicans (19.40%), C. glabrata (11.94%), C. parapsilosis (5.97%) and C. guillermondii (1.49%). Low birth weight and previous antibiotic prophylaxis was found in 100% cases. Crude mortality rate was 50.1%. By DD method, 95.53% of the Candida isolates were sensitive to fluconazole. A discrepancy between DD method and BMD-MIC method was noted in 4.47% strains. One isolates each of C. tropicalis, C. albicans, and C. glabrata showed discrepancy.

Conclusion:

Nonalbicans Candida has emerged as an important cause of neonatal septicemia. Routine susceptibility testing of Candida isolates by DD method should be confirmed by BMD-MIC method. Fluconazole can be used as empirical therapy for neonatal candidemia at our center.

Keywords

Antifungal sensitivity
nonalbicans Candida
neonatal septicemia

INTRODUCTION

Importance of Candida species in nursery and intensive care units (ICUs) is increasingly being recognized. Candida species account for 9-13% of all blood isolates in neonatal intensive care units (NICUs).[1] Although C. albicans has historically been the most frequently isolated species, infections caused by the nonalbicans Candida have been diagnosed with increasing frequency in recent years, notably C. tropicalis, C. glabrata, and C. parapsilosis. Common use of broad-spectrum antibiotics, low birth weight (LBW), prematurity, and intravenous catheter, etc., makes neonates prone to candidemia.[2] The incidence and associated mortality due to candidemia can be influenced by several factors including characteristic of the population at risk, standard of the health care facilities available, distribution of Candida species, and prevalence of antifungal resistance.[3] These factors may vary from one geographical region to other. The increased isolation rates of nonalbicans Candida species and a gradual shift in the antifungal susceptibility profile have underlined the need to monitor laboratory data for possible emergence of resistance and to select most appropriate antifungal agent for therapy. We have noticed an increased isolation rate of nonalbicans Candida from neonatal septicemia cases over last few months. So we are presenting our findings that were observed while investigating the causes of candidemia in a neonatal ICU.

MATERIALS AND METHODS

A total of 825 clinically suspected cases of neonatal septicemia were included in the study from June 2008-December 2008. Demographic and clinical data such as age, sex, birth weight, antibiotic prophylaxis, presence of CVC, and clinical outcome of the neonates were noted from clinical records. Approximately 1 to 2 ml of blood was collected under aseptic precautions and inoculated in biphasic brain heart infusion medium. Subculture was done on third, fifth, and seventh day. All the Candida isolates were subjected to germ tube test using normal human serum. Colonies were identified up to the species level on the basis of morphology on Corn meal agar, growth on Hi- CHROME Candida agar, carbohydrate fermentation, and assimilation patterns.[4] All the isolates were screened for antifungal susceptibility testing by the Disk Diffusion (DD) method using fluconazole (25 µg) (Hi- media, Mumbai) on Mueller-Hinton agar (MHA) supplemented with 2% glucose and methylene blue (GMB) 5 µg/ml. Zone diameters were interpreted as per the approved NCCLS (M44-A) guidelines.[5] The broth micro dilution-minimum inhibitory concentration (BMD-MIC) of the isolates was performed to the fluconazole using RPMI medium and MOPS buffer. MIC results were interpreted as per NCCLS (M27-A2) guidelines.[6] Isolates showing MIC # 8 µg/ml were regarded as susceptible, 16-32 µg/ ml as dose-dependent susceptible and $ 64 µg/ml as resistant. The quality control test was performed by using C. parapsilosis (ATCC 22019), C. krusei (ATCC 6258), and C. albicans (ATCC 90028).

RESULTS

A total of 67 (8.1%) Candida isolates were recovered from 825 specimens. Male to female ratio was 2:1. The mean age of neonates was 3.8 days (SD ± 5.9). All the neonates (100%) were low birth weight (between 1.0-1.5 kg), and had received prophylactic antibiotics. Other associated findings were presence of central venous line in 71%, prematurity 40%, perinatal asphyxia 31.2%, jaundice 27.8%, and meconium aspiration in 10.8% of neonates; crude mortality rate was 50.1%. One isolate was from HIV positive neonate. Majority of isolates were C. tropicalis (61.19%), followed by C. albicans (19.40%), C. glabrata (11.94%), C. parapsilosis (5.97%), and C. guillermondii (1.49%). The result of in vitro susceptibility testing of Candida isolates to fluconazole is shown in Table 1. By DD method, 89.55% of Candida isolates were sensitive to fluconazole. The results of antifungal susceptibility testing by DD and BMD-MIC were compared for fluconazole. The DD testing performed in accordance with NCCLS M 44-A guidelines was comparable in 95.53% strains. A discrepancy between DD method and BMD-MIC test result for susceptibility to fluconazole was noted in 4.47% strains.

Table 1: Comparison of antifungal susceptibility testing of Candida isolates by DD and BmD-MIC method
Species/No. of isolates n = 67 Test method Fluconazole (%)
S SDD R
C. tropicalis (41) DD 87.80 (36) 9.75 (4) 2.43 (1)
MIC 92.68 (38) 7.31 (3) 0.00
C. albicans (13) DD 92.3 (12) 0.00 0.00 1
MIC 100 (13) 0.00 0.00
C. glabrata (8) DD 25 (2) 12.5 (1) 62.5 (5)
MIC 50 (4) 0.00 50 (4)
C. parapsilosis (4) DD 100 (4) 0.00 0.00
MIC 100 (4) 0.00 0.00
C. guillermondii (1) DD 100 (1) 0.00 0.00
MIC 100 (1) 0.00 0.00

Numbers are in parenthesis; S - Sensitive; SDD - Susceptible dose dependant; R - Resistant

DISCUSSION

In our study, isolation rate of Candida from neonatal septicemia cases was 8.1%, which was lower than several other reports showing frequency of isolation in 13.6-19.6% cases.[2] C. albicans was the predominant organism in the earliest population based study conducted during 1992-1993 by CDC USA.[7] But a notable feature of our study was the emergence of nonalbicans Candida (80.59%) as a major cause of neonatal candidemia. C. tropicalis (61.19%) was the most common species followed by C. albicans (19.40%), and C. glabrata (11.94%). Our findings are supported by other studies from the same geographical area that have documented predominance of nonalbicans Candida over the C. albicans in neonatal septicemia.[8,9]

Antifungal susceptibility testing in our study revealed that all the Candida isolates except C. glabrata were 100% sensitive to fluconazole, though, three isolates of C. tropicalis were found to be in the Susceptible Dose Dependant (SDD) range with MIC 16 µg/ml, when tested by broth micro-dilution MIC method. In contrast to our study, several other Indian studies have reported a high (18.75-24%) fluconazole resistance against all the Candida spp.[10] The results of DD susceptibility testing to fluconazole were compared by BMD-MIC method. Overall, four strains of C. tropicalis were SDD by DD method that was reduced to three with BMD-MIC method. One strain of C. tropicalis that was resistant by DD method was found to be SDD with MIC 16 µg/ml. This result of our study emphasizes that DD method alone gives false resistance. Several risk factors have been cited as predisposing to candidemia in neonates including underlying illness, LBW, broad-spectrum antibiotic, asphyxia neonatorum, hyperalimentation, and total parentral nutrition.[2] In our study, LBW and broad spectrum antibiotic were the most common associated findings present in 100% neonates with candidemia.

CONCLUSION

Our study shows that nonalbicans Candida has emerged as a major cause of neonatal candidemia. LBW and broad spectrum antibiotics are the most common predisposing factors. Routine susceptibility testing of Candida isolates by DD method should be confirmed by BMD-MIC method. Fluconazole can be used as empirical therapy for neonatal candidemia at our center.

Source of Support:

Nil

Conflict of Interest:

None declared.

REFERENCES

  1. , , , . Candida glabrata emerging pathogen in neonatal sepsis. Ann Trop Med Public Health. 2008;1:5-8.
    [CrossRef] [Google Scholar]
  2. , , , . Trends in neonatal septicemia: Emergence of non-albican Candida. Indian Pediatr. 2004;41:712-5.
    [Google Scholar]
  3. . The global epidemiology of invasive Candida infections: Is the tide turning? J Hosp Infect. 2003;20:159-68.
    [CrossRef] [PubMed] [Google Scholar]
  4. . Candidiasis. In: A text book of medical mycology (3rd). New Delhi: Mehta Publishers; . p. :266-90.
    [Google Scholar]
  5. . Methods for antifungal disk diffusion susceptibility testing yeast: Approved guideline M-44A. Wayne, PA: NCCLS; .
    [Google Scholar]
  6. . Reference method for broth dilution testing of yeast approved standard. In: M27-A2 (2nd). Wayne, PA: NCCLS; .
    [Google Scholar]
  7. , . Microbiology of systemic fungal infection. J Postgrad Med. 2005;51:16-20.
    [Google Scholar]
  8. , , , , . Epidemiology of candidemia in a tertiary care centre of North India: 5-year study. Infection. 2007;35:256-9.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , . Candida glabrata emerging pathogen in neonatal sepsis. Ann Trop Med Pub Health. 2008;1:5-8.
    [CrossRef] [Google Scholar]
  10. , , . Neonatal systemic candidiasis in a tertiary care hospital. Indian J Med Microbiol. 2003;21:56-8.
    [Google Scholar]
Show Sections